Hormona key facts
as of Oct 2026- Developer of a femtech-based platform designed to improve female health and well-being.
- Hormona is valued at approximately $20.3M as of Oct 2026 (last reported valuation).
- It has raised $12.3M; the latest was Later Stage VC ($10.4M) in May 2025.
- Notable investors include Techstars, SFC Capital, DLF Venture, Advenimus AB, Blackheath Capital — 10 tracked in total.
- Status: Privately Held (backing).
Hormona's last reported valuation, May 2025. Nothing priced has surfaced since.
- ·Watch Hormona: the Monday email on marks, rounds and moves
Hormona funding rounds
No funding rounds for Hormona are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Hormona valuation
Hormona's last reported valuation was $20.3 million in May 2025. No priced round, secondary trade or fund mark has surfaced since.
Hormona investors
10 investors are on record for Hormona, including Techstars, SFC Capital, DLF Venture and Advenimus AB.
About Hormona
Developer of a femtech-based platform designed to improve female health and well-being. The company's technology allows women to take control of their health through daily measurement, tracking, and insights that optimize their well-being, enabling users to track their hormones and confidently manage their lives.
- Sector
- Consumer Products and Services (B2C)
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 12
- Website
- hormona.io/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.